Kisspeptin

CNot approvedkisspeptin-10kisspeptin-54metastin
In one paragraphKisspeptin is the hormone that switches on the reproductive axis: it makes the hypothalamus release GnRH, which drives LH, FSH and the sex hormones. In people it reliably raises LH within minutes, has been used as an egg-maturation trigger in IVF in phase 2 trials, and in two small randomised crossover trials at Imperial College London (32 women, 32 men) increased sexual-brain activation and reduced sexual aversion in people with low sexual desire. All of that is research-scale. It is not an approved medicine anywhere and is prohibited for male athletes.
Schematic 3D structure of Kisspeptin
10 residues · kisspeptin-10, the active C-terminal fragment · schematic
Overall gradeC Weak
Human trials10+ small studies
Outcomes graded5
Last reviewed3 September 2026
EvidenceWhat it isHow it worksUnknownsRegulationQuestionsReferences

What the human research shows

An honest C: the physiology is real and reproducible, but the clinical studies are single-centre, small, mostly single-dose, and mostly measure hormones or brain scans rather than outcomes people care about. The 'research' vials sold online have nothing to do with these trials.

OutcomeGradeEffect sizeHuman studiesWhere the evidence comes from
LH and testosterone releaseBProbableLargeMany small studiesSingle doses of kisspeptin-10 or -54 raise LH within 30 minutes in healthy men and women — one of the most reproducible findings in human neuroendocrinology. Continuous exposure desensitises the response.1
IVF egg maturation triggerCWeakModerate2 phase 2 trialsKisspeptin-54 as the final maturation trigger in 53 and then 60 women at high risk of ovarian hyperstimulation: live births achieved with no cases of severe OHSS. Not compared head-to-head with standard triggers at scale.2
Sexual desire (women with HSDD)CWeakSmall1 crossover RCT (n=32)Two-visit double-blind crossover in 32 premenopausal women: kisspeptin infusion increased activation in sexual-processing brain regions on fMRI and reduced sexual aversion scores. A mechanism study, not a treatment trial.3
Sexual desire and arousal (men with HSDD)CWeakSmall1 crossover RCT (n=32)Same design in 32 men: increased sexual-brain activation and a modest increase in penile tumescence to erotic stimuli. Single infusion; no data on repeated use.4
SafetyadverseCWeakNot measurableSmall studiesNo side effects reported in the HSDD trials; the fertility studies reported no severe OHSS. Nothing is known about repeated self-administration.34
AMultiple good human trials, consistentBSome human trials, mostly consistentCFew or weak human studiesDAnimal or anecdotal onlyeffect size · red = adverse

Literature searched to 3 September 2026. Human studies only; animal and cell work informs the mechanism section and nothing else.

What it is

A family of peptides encoded by the KISS1 gene — the full 54-amino-acid form and shorter fragments such as kisspeptin-10 — acting on the KISS1R receptor on GnRH neurons. Loss-of-function mutations cause absent puberty, which is how its role was discovered in 2003.

Almost all the human work comes from one group, at Imperial College London, using intravenous or subcutaneous infusions in a research setting. No company has taken a kisspeptin product through phase 3.

How it is thought to work

Kisspeptin neurons in the hypothalamus are the master switch for GnRH pulses. A dose produces a pulse of LH (and, in men, testosterone) about half an hour later; because the system desensitises, continuous dosing switches the axis off — the same paradox exploited by GnRH agonists.

Its receptors are also found in limbic brain regions involved in sexual and emotional processing, which is the rationale for the HSDD studies.

What is still unknown

  • Whether any of the mechanistic findings translate into a treatment that works over weeks.
  • Effects of repeated dosing on the reproductive axis outside a trial.
  • The purity and identity of anything sold as kisspeptin online.

Regulatory status

European Union
Unauthorised medicinal product

No marketing authorisation. Supplying it for human use is an offence under national medicines law.

United States
Not approved; compounding barred

Kisspeptin-10 remains in Category 2 of the FDA's 503A list (significant safety risks) as of April 2026 — it may not be compounded.

United Kingdom
Unlicensed medicine

Used only in academic trials; supply for human use is an offence.

Australia
Schedule 4, unapproved

Prescription-only substance not on the ARTG.

Canada
Not authorised

No DIN; selling it is illegal.

Sport (WADA)
Prohibited at all times (males)

S2.2.1: 'kisspeptin and its agonist analogues', prohibited in males as an LH/testosterone releaser.

Questions people actually ask

Does kisspeptin increase testosterone?
Acutely, yes: a single dose reliably raises LH and then testosterone in men within an hour or two. Repeated or continuous exposure desensitises the axis and can lower it. That acute effect is why it is banned for male athletes.
Is kisspeptin a treatment for low libido?
Not yet. Two single-dose crossover trials in 32 women and 32 men showed increased sexual-brain activation and reduced sexual aversion. They were designed to test a mechanism, not to treat anyone, and no trial has tested weeks of use.
Is kisspeptin used in IVF?
In research. Phase 2 trials used kisspeptin-54 as the trigger for final egg maturation in women at high risk of ovarian hyperstimulation, with live births and no severe OHSS. It is not a standard-of-care trigger.

One page per claimed effect

References

  1. 1
  2. 2
  3. 3
    Thurston L, et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial.JAMA Netw Open, 2022; DOI 10.1001/jamanetworkopen.2022.3613132 premenopausal women, double-blind crossover.
  4. 4

Change log

  • 2026-09-03Initial publication from the Imperial College physiology, IVF and HSDD trials.